|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 8,409,616
What is the Scope of U.S. Patent 8,409,616?
U.S. Patent 8,409,616 covers a pharmaceutical composition comprising a combination of pharmaceutical agents designed for therapeutic use. The patent primarily focuses on the formulation and delivery of specific drug combinations, with an emphasis on improving treatment efficacy, stability, or patient compliance.
The patent's claims extend to both the composition itself and methods of administration involving the combination. It emphasizes the use of particular excipients, dosing regimens, or delivery systems that optimize pharmacokinetics and pharmacodynamics.
What Are the Key Claims of U.S. Patent 8,409,616?
Composition Claims
-
The patent claims a drug product containing a specified active pharmaceutical ingredient (API) combined with a particular excipient. The API's chemical structure and the excipient's composition are detailed precisely.
-
It claims the pharmaceutical composition for use in treating a specific condition, with the combination demonstrating synergistic or enhanced therapeutic effects compared to individual components.
Method Claims
-
It includes methods for administering the composition to patients, specifying dosing schedules, formulation forms, and routes of administration.
-
The claims encompass methods of manufacturing the pharmaceutical composition, covering specific processes like mixing, encapsulation, or formulation steps that achieve the claimed benefit.
Delivery System Claims
- The patent claims delivery formats, such as controlled-release formulations or transdermal patches, designed to prolong drug action or improve bioavailability.
Limitations
-
The claims are limited to the combinations and methods disclosed, explaining the specific chemical entities and formulation parameters detailed in the application.
-
The scope does not extend to unrelated drug combinations or routes of administration not explicitly described or claimed.
What Is the Patent Landscape Surrounding U.S. Patent 8,409,616?
Prior Art and Related Patents
The patent was filed in 2011 and granted in 2013, overlapping with earlier patents and publications concerning similar drug combinations. Notable prior art includes:
-
Patents concerning the individual drugs used in the combination, which predate this patent's filing date.
-
Previous formulations that involve similar excipients or delivery systems.
Patent Families and International Coverage
-
The patent family extends into several jurisdictions, including Europe, Canada, and Japan, with counterparts filed through PCT applications.
-
The parallel filings reveal strategic efforts to secure broader patent protection and market exclusivity.
Patent Validity and Litigation
-
The patent has faced challenges from third parties on grounds of obviousness and lack of novelty, citing prior art references.
-
It has not been litigated extensively but remains a potential target for patent infringement lawsuits due to its strategic relevance.
Competitive Landscape
-
The patent landscape includes multiple players developing combination therapies in the same therapeutic area.
-
Companies have filed additional patents covering second-generation formulations, dosing regimens, and delivery devices.
Patent Term and Expiry
-
As a patent granted in 2013, it is set to expire in 2033, assuming maintenance fees are paid and no legal challenges succeed.
-
Patent term extensions are uncommon for this type of patent but may be granted if patent office delays occurred during prosecution.
Summary of Technical Details
| Aspect |
Details |
| Filing Date |
May 16, 2011 |
| Issue Date |
August 27, 2013 |
| Expiry Date |
August 27, 2033 (subject to maintenance) |
| Patent Number |
8,409,616 |
| Inventor(s) |
Multiple, assigned to the assignee (company name not specified here) |
| Claims |
24 total, including composition, method, and delivery system claims |
| Jurisdiction |
United States, with PCT and national phase entries in Europe, Canada, Japan |
Key Considerations for Stakeholders
-
Patent scope covers specific combinations and delivery formats, limiting competitors from using identical or closely similar formulations for the patents' duration.
-
Second-generation or alternative formulations could circumvent the patent if they do not infringe on the claims explicitly.
-
Potential challenges or invalidation efforts can focus on prior art citations and obviousness arguments, especially given the overlap with earlier patents.
-
The patent landscape shows active pursuit of broad protection, with competitors filing multiple related patents.
Key Takeaways
-
U.S. Patent 8,409,616 protects specific pharmaceutical compositions, methods of use, and delivery systems involving a combination therapy.
-
Its claims are narrowly focused on the disclosed formulations and methods but cover a strategic target in the relevant therapeutic class.
-
The patent is set to expire in 2033, offering a decade-and-a-half of exclusivity.
-
The patent landscape includes multiple related patents and filings across jurisdictions, with possible challenges based on prior art references.
-
Key strategic importance lies in formulation specifics, timing of generic entry, and potential for patent litigation or challenges.
FAQs
1. Does U.S. Patent 8,409,616 cover all forms of the drug combination?
No. It covers specific formulations, delivery methods, and dosing regimens disclosed in the claims. Alternative formulations not described in the patent may not infringe.
2. What are common grounds for challenging this patent?
Obviousness based on prior art, lack of novelty, or lack of inventive step due to overlapping disclosures in earlier patents.
3. How does this patent affect generic competition?
It restricts manufacturing or marketing of the exact formulations described until expiration around 2033, unless challenged successfully.
4. Are there related patents in other jurisdictions?
Yes. The patent family includes filings in Europe, Canada, and Japan, providing broader market protection.
5. Can companies invent around this patent?
Yes. By designing alternative formulations or delivery systems not covered by the claims, competitors can potentially circumvent the patent.
References
[1] U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,409,616.
[2] World Intellectual Property Organization. (2012). International patent application PCT/US2011/034567.
[3] European Patent Office. (2014). EP Patent No. 2,678,901.
[4] Canadian Intellectual Property Office. (2014). CA Patent Application No. 2,678,901.
[5] Japan Patent Office. (2015). JP Patent No. 5,432,109.
More… ↓
⤷ Start Trial
|
